All In Biotech

Drug Trial Radar · NCT05963984

A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants

An Open-label, Interventional, Multicenter, Randomized, Phase 2 Study of Fulvestrant With or Without Samuraciclib in Participants With Metastatic or Locally Advanced Hormone Receptor (HR) Positive and Human Epidermal Growth Factor Receptor (HER)2-Negative Breast Cancer (BC)

Last checked: Nov 19, 2026Latest source record: Dec 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

60

Actual

Start

Nov 16, 2023

Primary completion

Mar 20, 2025

Study completion Aug 28, 2025

Sponsor

Lead sponsor
Carrick Therapeutics LimitedIndustry
Sponsor type
Industry
Collaborators
Pfizer
First posted
Jul 27, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of samuraciclib in combination with fulvestrant versus fulvestrant alone in adult participants with metastatic or locally advanced Hormone Receptor (HR) positive and Human Epidermal Growth Factor Receptor (HER)2-negative breast cancer.

Conditions

  • Metastatic Breast Cancer
  • Locally Advanced Breast Cancer
  • Breast Cancer

Interventions

  • SamuraciclibDrug

    Samuraciclib tablet by mouth once a day

  • FulvestrantDrug

    Injection administered monthly (i.e., every 4 weeks), plus additional dose at Cycle 1 Day 15

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical Benefit Response (CBR)Time frame: From randomization until Week 24

Locations

32 sites in 5 countries. Site status is shown where the registry gives one.

  • Ocala Oncology Center PL DBA Florida Cancer Affiliates

    Ocala, Florida

  • Mfsmc-Hjwci

    Baltimore, Maryland

  • Saint Luke's Cancer Institute

    Kansas City, Missouri

  • Sidney Kimmel Cancer Center - Jefferson Health

    Philadelphia, Pennsylvania

  • The Center for Cancer and Blood Disorders

    Fort Worth, Texas

  • Semmelweis Egyetem

    Budapest, Hungary

  • Szent Borbala Korhaz

    Tatabánya, Komárom-Esztergom, Hungary

  • Nograd Varmegyei Szent Lazar Korhaz

    Salgótarján, Nógrád megye, Hungary

  • Cryptex Investigación Clínica S.A. de C.V.

    Cuauhtémoc, Mexico

  • Oaxaca Site Management Organization S.C.

    Oaxaca City, Mexico

  • Centro de Investigacion Clinica de Oaxaca

    Oaxaca City, Mexico

  • Actualidad Basada en la Investigación del Cáncer

    Guadalajara, Jalisco, Mexico

  • Renati Innovation S.A.P.I de C.V

    Guadalajara, Jalisco, Mexico

  • Soltmed SMO

    Mexico City, Mexico City, Mexico

  • Hospital Infanta Cristina

    Badajoz, Spain

  • Parc de Salut Mar - Hospital del Mar

    Barcelona, Spain

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain

  • MD Anderson Cancer Center

    Madrid, Spain

  • Hospital Vithas Málaga

    Málaga, Spain

  • Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca

    Salamanca, Spain

  • Hospital Clinico de Valencia

    Valencia, Spain

  • Institut Català d'Oncologia - L'Hospitalet

    L'Hospitalet de Llobregat, Barcelona, Spain

  • Hospital Universitario Marqués de Valdecilla

    Santander, Cantabria Comunidad de, Spain

  • Hospital Clinico San Carlos

    Madrid, Madrid, Comunidad de, Spain

  • Gulhane Egitim ve Arastirma Hastanesi

    Ankara, Turkey (Türkiye)

  • Gazi University

    Ankara, Turkey (Türkiye)

  • Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastırma Hastanesi

    Ankara, Turkey (Türkiye)

  • Hacettepe Universite Hastaneleri

    Ankara, Turkey (Türkiye)

  • Trakya University

    Edirne, Turkey (Türkiye)

  • Istanbul Universitesi Istanbul Tıp Fakultesi Hastanesi

    Istanbul, Turkey (Türkiye)

  • TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi

    Istanbul, Turkey (Türkiye)

  • I.E.U. Medical Point Hastanesi

    Izmir, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.